**To the Editor:** Since 2003, outbreaks of *Clostridium difficile--*associated disease (CDAD) associated with the emergence of a hypervirulent strain have been reported worldwide (*1,2*; [www.eurosurveillance.org/em/v12n06/1206-221.asp](http://www.eurosurveillance.org/em/v12n06/1206-221.asp)). This strain has been associated with increased disease severity and attributable mortality. Patients infected with *C. difficile* 027 fail to respond to metronidazole therapy ([@R1]). Several typing methods have been applied to further characterize *C. difficile* PCR ribotype-027, including pulsed-field gel electrophoresis (PFGE) (North American pulsed field type 1) and restriction enzyme analysis (REA) (BI). PFGE and REA are widely used in the United States; PCR ribotyping is more commonly used throughout Europe. More recently, 2 multiple-locus variable-number tandem-repeat analysis (MLVA) protocols have been applied to type *C. difficile,* and these proved more discriminatory compared to other methods ([@R3],[@R4]). Furthermore, MLVA can subgroup geographically diverse 027 isolates (G. Killgore et al., unpub data) as well as 027 isolates that are common to 1 institution ([@R5]).

We reported a case of *C. difficile* PCR 027 in Ireland, where the isolate had an identical antibiogram profile compared with those strains reported across Europe ([@R6],[@R7]) (i.e., resistant to fluoroquinolones and erythromycin, susceptible to clindamycin). We have subsequently identified *C. difficile* 027 in 6 more healthcare settings. To date \>100 Irish *C. difficile* 027 isolates have been characterized by analysis of their antibiogram profiles, toxinotyping, and 16S--23S rDNA PCR ribotyping. All *C. difficile* 027 isolates were resistant to moxifloxaxin, gatifloxacin, ciprofloxacin (MIC \>32 mg/L), and erythromycin (MIC \>256 mg/L) but susceptible to metronidazole (MIC 0.25 mg/L) and vancomycin (MIC \>0.5 mg/L). Clindamycin susceptibility varied between isolates from unrelated institutions. Isolates from 2 healthcare settings were susceptible to clindamycin (n = 11: MIC~90~ 4 mg/L). However, clindamycin-resistant PCR 027 isolates (n = 96: MIC~90~ \>256 mg/L) were identified in the other 5 healthcare institutions. All clindamycin-resistant PCR 027 isolates were positive for the *erm*B gene, encoding the macrolide-lincosamide-streptogramin-B genotype.

A subset of clindamycin-sensitive and -resistant Irish 027 strains isolated throughout 2006 (n = 22) were further characterized by using a recently described MLVA protocol ([@R3]). Six clindamycin-susceptible isolates were selected from 2 healthcare settings. One hospital conducted active routine laboratory surveillance and molecular genotyping (n = 3). The second hospital submitted only random isolates (n = 3) for typing during a *C. difficile* outbreak. Sixteen clindamycin-resistant PCR 027 isolates were also included in the MLVA. Resistant isolates were selected from 5 healthcare settings. These included isolates from 2 *C. difficile* outbreaks with ongoing laboratory surveillance (n = 5, n = 6, respectively); a third hospital with ongoing laboratory surveillance (n = 3) and 2 hospitals that each submitted fecal samples from patients with severe cases of *C. difficile* disease (n = 1). The Stoke-Mandeville control strain R20291 was included for comparison.

MLVA determined that all strains within the clindamycin-resistant cluster were closely related and were single- or double-locus variants with a maximum 5 summed tandem-repeat difference (STRD). In contrast, the closest relationship between the clindamycin-resistant and the clindamycin-sensitive clusters was a triple-locus variant with an STRD of 17. The nonrelated reference strain of the Stoke-Mandeville outbreak (R20291) differed considerably from all Irish isolates but was more related to the clindamycin-sensitive cluster than to the clindamycin-resistant cluster ([Figure](#F1){ref-type="fig"}). We thus linked a defined genetic marker with the clindamycin-resistant phenotype in *C. difficile* PCR-027. MLVA could clearly differentiate clindamycin-resistant and -susceptible isolates from the same geographic region and subgrouped them into 2 distinct clusters ([Figure](#F1){ref-type="fig"}).
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Although high-level resistance to fluoroquinolone antimicrobial agents has been well documented in PCR 027 ([@R1],[@R6]), resistance to clindamycin is rare. Subsequently, clindamycin has been considered as a "protective" antimicrobial agent for the development of CDAD in an epidemiologic survey in the Netherlands ([@R8]). Currently, resistance to this agent in NAP 1/PCR 027 has been restricted to the United States. McDonald and colleagues reported that 19 (79%) of 24 NAP 1 isolates were classified as less susceptible (MIC 4 mg/L) or resistant (MIC 8 mg/L) to clindamycin when Clinical and Laboratory Standards Institute criteria were used ([@R2]). Unfortunately, MIC values were not reported, and the corresponding resistance genes were not investigated. In contrast, Canadian studies to date have not reported clindamycin resistance in this strain type. The MIC~90~ of Canadian NAP 1 isolates for clindamycin was 4 mg/L ([@R9],[@R10]). Although outbreaks and sporadic cases of PCR 027 have been identified in several European countries, to date no clindamycin-resistant clone has been reported.

Detection of clindamcyin-resistant *C. difficile* PCR 027 strains is an important and worrying development. Resistance to this antimicrobal agent increases the risk for CDAD in patients, and its use may be an important factor contributing to the persistence and spread of PCR 027. A similar feature has already been observed when fluoroquinolones and cephalosporins are prescribed. Clindamcyin-resistant PCR 027 probably reflects the emergence of a new clone because MLVA clearly differentiates between clindamycin-susceptible and -resistant isolates.
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